Publications (167) Salvador Martín Algarra publications

filter_list

2026

  1. Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer

    The Journal of clinical investigation, Vol. 136, Núm. 9

  2. Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry

    Clinical and Translational Oncology, Vol. 28, Núm. 2, pp. 645-653

  3. Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801

    Clinical and Translational Oncology, Vol. 28, Núm. 5, pp. 1807-1814

  4. Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801)

    Clinical and Translational Oncology, Vol. 28, Núm. 1, pp. 320-329

  5. Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801

    Clinical and Translational Oncology, Vol. 28, Núm. 6, pp. 2377-2385

2025

  1. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

    Clinical and Translational Oncology, Vol. 27, Núm. 1, pp. 386-391

  2. Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey

    The Lancet Oncology

  3. Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study

    Melanoma Research, Vol. 35, Núm. 6, pp. 399-408

2024

  1. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

  2. Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes

    Endocrine-related cancer, Vol. 31, Núm. 10

2023

  1. Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 14, pp. 2561-2570

  2. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

    Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 768-775

  3. Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study

    European Journal of Cancer, Vol. 190

2021

  1. Diffuse dermal mucinosis secondary to colony-stimulating factor 1 receptor monoclonal antibody treatment: A novel and peculiar drug-induced diffuse cutaneous mucinosis

    Journal of Dermatology, Vol. 48, Núm. 3, pp. 380-384

  2. Erratum: Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma (Cancer Cell (2020) 38(4) (500–515.e3), (S1535610820304165), (10.1016/j.ccell.2020.08.005))

    Cancer Cell

  3. Evaluation of patient quality care in Spain in prevention of nausea and vomiting induced by chemotherapy

    Journal of Healthcare Quality Research, Vol. 36, Núm. 3, pp. 142-149

  4. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

    Journal of Clinical Oncology, Vol. 39, Núm. 24, pp. 2656-2666

  5. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 6, pp. 586-598

2020

  1. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

    Cancer Cell, Vol. 38, Núm. 4, pp. 500-515.e3

  2. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565